PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1546126
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1546126
Dengue Vaccines Market Size- By Type of Vaccine, By Vaccine Phase, By Distribution Channel- Regional outlook, Competitive Strategies and Segment Forecast to 2033
Dengue Vaccines Market Introduction and Overview
According to SPER Market Research, 'Dengue Vaccines Market Size- By Type of Vaccine, By Vaccine Phase, By Distribution Channel - Regional outlook, Competitive Strategies and Segment Forecast to 2033' States that the Global Dengue Vaccines Market is estimated to reach USD 1813.95 million by 2033 with a CAGR of 13.11 %.
Dengue vaccines are designed to prevent dengue fever, a tropical illness spread by Aedes mosquitoes. The primary challenge in developing these vaccines lies in addressing the four different dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
The focus on COVID-19 diverted resources, funding, and research efforts away from other infectious diseases, including dengue. This shift has slowed progress in the development and approval of new dengue vaccines.
Scope of the report:
Report Metric Details
Market size available for years 2020-2033
Base year considered 2023
Forecast period 2024-2033
Segments covered By Type of Vaccine, By Vaccine Phase, By Distribution Channel
Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
Companies Covered Butantan Institute, GeneOne Life Science Inc., GlaxoSmithKline Plc, Mylan N.V., Medigen Vaccine Biologics Corporation, Merck and Co. Inc., Nunn's Home Medical Equipment Company Ltd., Panacea Biotec Limited, Sanofi Pasteur Limited, Serum Institute of India Pvt Ltd.
Global Dengue Vaccines Market Segmentation:
By Type of Vaccine: Based on the Type of Vaccine, Global Dengue Vaccines Market is segmented as; Live Attenuated Vaccines, Recombinant Vaccines.
By Vaccine Phase: Based on the Vaccine Phase, Global Dengue Vaccines Market is segmented as; Phase I, Phase II, Phase III.
By Distribution Channel: Based on the Distribution Channel, Global Dengue Vaccines Market is segmented as; Hospitals, Clinics, Retail Pharmacies.
By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 4.2. COVID-19 Impacts of the Global Dengue Vaccines Market
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Dengue Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type of Vaccine
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Dengue Vaccines Market
7. Global Dengue Vaccines Market, By Type of Vaccine (USD Million) 2020-2033
- 7.1. Global Dengue Vaccines Market Size, Share and Forecast, By Type of Vaccine, 2020-2026
- 7.2. Global Dengue Vaccines Market Size, Share and Forecast, By Type of Vaccine, 2027-2033
- 7.3. Live Attenuated Vaccines
- 7.4. Recombinant Vaccines
8. Global Dengue Vaccines Market, By Vaccine Phase (USD Million) 2020-2033
- 8.1. Global Dengue Vaccines Market Size, Share and Forecast, By Vaccine Phase, 2020-2026
- 8.2. Global Dengue Vaccines Market Size, Share and Forecast, By Vaccine Phase, 2027-2033
- 8.3. Phase I
- 8.4. Phase II
- 8.5. Phase III
9. Global Dengue Vaccines Market, By Distribution Channel (USD Million) 2020-2033
- 9.1. Global Dengue Vaccines Market Size, Share and Forecast, By Distribution Channel, 2020-2026
- 9.2. Global Dengue Vaccines Market Size, Share and Forecast, By Distribution Channel, 2027-2033
- 9.3. Synthetic
- 9.4. Bio-Based
10. Global Dengue Vaccines Market Forecast, 2020-2033 (USD Million)
- 10.1. Global Dengue Vaccines Market Size and Market Share
11. Global Dengue Vaccines Market, By Region, 2020-2033 (USD Million)
- 11.1. Global Dengue Vaccines Market Size and Market Share By Region (2020-2026)
- 11.2. Global Dengue Vaccines Market Size and Market Share By Region (2027-2033)
- 11.3. Asia-Pacific
- 11.3.1. Australia
- 11.3.2. China
- 11.3.3. India
- 11.3.4. Japan
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
- 11.4. Europe
- 11.4.1. France
- 11.4.2. Germany
- 11.4.3. Italy
- 11.4.4. Spain
- 11.4.5. United Kingdom
- 11.4.6. Rest of Europe
- 11.5. Middle East and Africa
- 11.5.1. Kingdom of Saudi Arabia
- 11.5.2. United Arab Emirates
- 11.5.3. Qatar
- 11.5.4. South Africa
- 11.5.5. Egypt
- 12.5.6. Morocco
- 11.5.7. Nigeria
- 11.5.8. Rest of Middle-East and Africa
- 11.6. North America
- 11.6.1. Canada
- 11.6.2. Mexico
- 11.6.3. United States
- 11.7. Latin America
- 11.7.1. Argentina
- 11.7.2. Brazil
- 11.7.3. Rest of Latin America
12. Company Profile
- 12.1. Butantan Institute
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. GeneOne Life Science Inc.
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. GlaxoSmithKline Plc
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. Mylan N.V.
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Medigen Vaccine Biologics Corporation
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Merck and Co. Inc.
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Nunn's Home Medical Equipment Company Ltd.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Panacea Biotec Limited
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Sanofi Pasteur Limited
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Serum Institute of India Pvt. Ltd.
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
13. Conclusion
14. List of Abbreviations
15. Reference Links
